Shares of Hims & Hers Health Inc. (HIMS) soared 5.14% on Monday after President-elect Donald Trump nominated Dr. Marty Makary to lead the Food and Drug Administration (FDA), boosting optimism about the company's prospects for selling compounded versions of popular weight-loss drugs.
Makary, a surgeon and chief medical officer for telehealth provider Sesame, has ties to the compounding pharmacy industry that offers alternatives to brand-name drugs like Novo Nordisk's Wegovy. Hims & Hers is among the telehealth companies benefiting from surging demand for compounded versions of Wegovy due to shortages and high costs of the branded drug.
With Makary's nomination, investors are betting that the new administration could adopt a more favorable stance toward compounding pharmacies, potentially allowing them to expand production of alternatives to expensive drugs. This could further boost demand for Hims & Hers' compounded offerings and drive growth for the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。